Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Tuesday.
According to Zacks, “Actinium Pharmaceuticals, Inc. is a biopharmaceutical company. It specializes in the development of cancer drugs. The company’s principal product candidates under different developmental stages include Actimab-A for the treatment of acute myeloid leukemia in elderly patients and Iomab-B used to condition the bone marrow of patients. Actinium Pharmaceuticals, Inc. is based in New York. “
ATNM has been the topic of several other research reports. Maxim Group reissued a “buy” rating on shares of Actinium Pharmaceuticals in a report on Thursday, June 14th. B. Riley set a $3.00 price target on shares of Actinium Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, May 23rd. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Actinium Pharmaceuticals has a consensus rating of “Buy” and an average price target of $3.70.
Actinium Pharmaceuticals traded down $0.05, hitting $0.58, on Tuesday, MarketBeat Ratings reports. The company’s stock had a trading volume of 3,297,987 shares, compared to its average volume of 1,010,593. Actinium Pharmaceuticals has a one year low of $0.33 and a one year high of $1.33.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Worth Venture Partners LLC bought a new stake in shares of Actinium Pharmaceuticals in the 1st quarter worth about $140,000. Sio Capital Management LLC acquired a new position in Actinium Pharmaceuticals during the 1st quarter worth about $393,000. Anson Funds Management LP acquired a new position in Actinium Pharmaceuticals during the 1st quarter worth about $1,502,000. Sabby Management LLC acquired a new position in Actinium Pharmaceuticals during the 1st quarter worth about $729,000. Finally, D.A. Davidson & CO. lifted its position in Actinium Pharmaceuticals by 227.1% during the 4th quarter. D.A. Davidson & CO. now owns 157,000 shares of the biotechnology company’s stock worth $104,000 after buying an additional 109,000 shares in the last quarter.
Actinium Pharmaceuticals Company Profile
Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older.
Get a free copy of the Zacks research report on Actinium Pharmaceuticals (ATNM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.